Raytheon awarded $71 million in Navy contracts for missile systems
Gilad Oren, President and CEO of Aprea Therapeutics, Inc. (NASDAQ:APRE), recently acquired additional shares of the company. On April 3, 2025, Oren purchased a total of 5,500 shares of Aprea’s common stock. The transaction was executed in two tranches, with prices per share ranging from $1.80 to $1.87, resulting in a total transaction value of $10,110. The purchase comes as the stock trades near its 52-week low of $1.74, having declined 45% year-to-date. According to InvestingPro analysis, the stock appears undervalued at current levels.
Following these acquisitions, Oren directly owns 345,620 shares of Aprea Therapeutics, representing a significant stake in the micro-cap company, which currently has a market value of $9.89 million. Additionally, through indirect holdings, he has beneficial interests in shares held by his daughter and son, although he disclaims beneficial ownership of these securities. InvestingPro subscribers can access 15 additional key insights about APRE’s financial health and market position.
In other recent news, Aprea Therapeutics has announced a partnership with MD Anderson Cancer Center to advance preclinical research on its WEE1 kinase inhibitor, APR-1051, aimed at treating head and neck squamous cell carcinoma. This collaboration will focus on evaluating the efficacy of APR-1051, especially in combination with immune checkpoint inhibitors, to support future clinical trials. Additionally, Aprea Therapeutics has expanded its patent portfolio, with its ATR inhibitor program, including ATRN-119, backed by a robust patent estate comprising several granted and pending patents. These patents are set to expire between 2035 and 2044, offering potential regulatory exclusivities that could extend the company’s market protection.
Aprea is also actively enrolling patients in the ACESOT-1051 Phase 1 clinical trial for APR-1051, with no reported hematologic toxicity so far, and expects to release safety and efficacy data by mid-2025. The ATRN-119 program is progressing in the ABOYA-119 study, which has completed its first five dose cohorts, showing preliminary clinical benefits at certain doses. H.C. Wainwright has reaffirmed its Buy rating for Aprea Therapeutics, setting a price target of $20.00, citing confidence in the company’s clinical pipeline and strategic focus. Aprea plans to disclose a third candidate, another DDR (NYSE:SITC) inhibitor, which could further expand its oncology pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.